← BriaCell Therapeutics Corp. (BCTX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
BriaCell Therapeutics Corp. (BCTX)
Pharmaceutical Preparations · market cap $36M · as of 2026-07-18
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-21 (est.)
Earnings
Pipeline
3
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
BriaCell Therapeutics Corp. (BCTX) is a micro-cap clinical-stage pharmaceutical company with a market cap of approximately $32M, developing SV-BR-1-GM as its lead asset in a Phase 3 trial for breast cancer. The company reports essentially no revenue, a cash position of only $6.9M, and an estimated runway of under one month, placing it in an acute liquidity crisis. No upcoming catalysts are calendared and no analyst coverage exists.
The catalyst path
- 2026-10-21 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| BC1 cell line | Phase 2 | Breast Cancer |
| SV-BR-1-GM | Phase 3 | Breastcancer |
| Interferon infiltration of the inoculation site | Phase 3 | Breast Cancer |
Price & technical context
3-month
+17.4%
6-month
+0.2%
12-month
-67.3%
52-wk range
$2.74–$13.79
vs 50-day MA
+10.4%
vs 200-day MA
-3.0%
Realized vol
126.1%
Max drawdown
-98.5%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for BCTX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.